Table 1 Demographic and clinic pathological descriptions for study populations
From: Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
Variables | Discovery set | Validation set | ||||
|---|---|---|---|---|---|---|
Harvard (N = 151) | Spain (N = 226) | Norway (N = 133) | Sweden (N = 103) | All (N = 613) | TCGA (N = 617) | |
Age (years), mean ± SD | 67.67 ± 9.92 | 65.67 ± 10.58 | 65.52 ± 9.34 | 67.54 ± 9.99 | 66.44 ± 10.08 | 66.51 ± 9.47 |
Gender, n (%) | * | |||||
Female | 67 (44.37) | 105 (46.46) | 71 (53.38) | 54 (52.43) | 297 (48.45) | 255 (41.33) |
Male | 84 (55.63) | 121 (53.54) | 62 (46.62) | 49 (47.57) | 316 (51.55) | 362 (58.67) |
Smoking status, n (%) | * | |||||
Never | 18 (11.92) | 30 (13.57) | 17 (12.78) | 18 (17.48) | 83 (13.65) | 55 (9.18) |
Former | 81 (53.64) | 120 (54.30) | 74 (55.64) | 54 (52.43) | 329 (54.11) | 376 (62.77) |
Current | 52 (34.44) | 71 (32.13) | 42 (31.58) | 31 (30.10) | 196 (32.24) | 168 (28.05) |
Unknown | 0 | 5 | 0 | 0 | 5 | 18 |
TNM stage, n (%) | * | |||||
I | 104 (68.87) | 183 (80.97) | 93 (69.92) | 95 (92.23) | 475 (77.49) | 393 (63.70) |
II | 47 (31.13) | 43 (19.03) | 40 (30.08) | 8 (7.77) | 138 (22.51) | 224 (36.30) |
Histology, n (%) | * | |||||
Adenocarcinoma (AC) | 96 (63.58) | 183 (80.97) | 133 (100.00) | 80 (77.67) | 492 (80.26) | 332 (53.81) |
Squamous cell carcinoma (SCC) | 55 (36.42) | 43 (19.03) | 0 (0.00) | 23 (22.33) | 121 (19.74) | 285 (46.19) |
Chemotherapy, n (%) | * | |||||
No | 142 (94.04) | 177 (90.77) | 102 (76.69) | 67 (90.54) | 488 (88.25) | 194 (76.98) |
Yes | 9 (5.96) | 18 (9.23) | 31 (23.31) | 7 (9.46) | 65 (11.75) | 58 (23.02) |
Unknown | 0 | 31 | 0 | 29 | 60 | 365 |
Radiotherapy, n (%) | ||||||
No | 132 (87.42) | 184 (94.36) | 132 (99.25) | 74 (100.00) | 522 (94.39) | 239 (94.84) |
Yes | 19 (12.58) | 11 (5.64) | 1 (0.75) | 0 (0.00) | 31 (5.61) | 13 (5.16) |
Unknown | 0 | 31 | 0 | 29 | 60 | 365 |
Adjuvant therapy, n (%) | * | |||||
No | 127 (84.11) | 168 (86.15) | 101 (75.94) | 67 (90.54) | 463 (83.73) | 187 (74.21) |
Yes | 24 (15.89) | 27 (13.85) | 32 (24.06) | 7 (9.46) | 90 (16.27) | 65 (25.79) |
Unknown | 0 | 31 | 0 | 29 | 60 | 365 |
Survival year, month | ||||||
Median (95%CI) | 6.66 (5.41–7.87) | 7.12 (5.06–9.63) | 7.36 (6.77–7.95)* | 7.39 (4.98–9.12) | 7.39 (6.50–8.23) | 4.54 (3.68–5.41) |
Dead, n (%) | 122 (80.79) | 101 (44.69) | 42 (31.58) | 58 (31.58) | 323 (52.69) | 142 (23.01) |